Entera Bio Ltd. (NASDAQ:ENTX) Q4 2021 Earnings Conference Call March 8, 2022 8:30 AM ET Company Participants Ramesh Ratan - CFO Spiros Jamas - CEO Arthur Santora - CMO Phillip Schwartz - Founder & President, R&D Conference Call Participants Kalpit Patel - B. Riley Nathan Weinstein - Aegis Capital Operator Greetings and welcome to the Entera Bio's Fourth Quarter and Year-End 2021 Earnings Call. At this time, all participants are in a listen-only mode. The question-and-answer session will follow the formal pr ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 001-38556 Entera Bio Ltd. (Exact Name of Registrant as Specified in Its Charter) Israel 00-0000000 (State or Other Jurisdiction of Incorp ...

Entera Bio Ltd. (NASDAQ:ENTX) Q2 2021 Earnings Conference Call August 16, 2021 8:30 AM ET Company Participants Spiros Jamas - CEO Ramesh Ratan - US-based CFO Arthur Santora - CMO Phillip Schwartz – President, R&D Conference Call Participants Kalpit Patel – B. Riley Financial, Inc. Operator Good morning, and welcome to Entera Bio's Conference Call to discuss the Financial and Operating Results for the six months Ended June 30, 2021. At this time, all participants are in a listen-only mode. After the speakers ...

Entera Bio Ltd. (NASDAQ:ENTX) Q4 2020 Earnings Conference Call March 18, 2021 8:30 AM ET Company Participants Jon Lieber – US-based Chief Financial Officer Spiros Jamas – Chief Executive Officer Art Santora – Chief Medical Officer Phillip Schwartz – President-R&D Conference Call Participants Jason McCarthy – Maxim Group Calvin Hori – Hori Capital Operator Good morning, and welcome to Entera Bio's Conference Call to discuss the Financial and Operating Results for the Year Ended December 31, 2020. At this tim ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ . OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 O ...

Entera Bio Ltd. (NASDAQ:ENTX) Q3 2020 Earnings Conference Call November 19, 2020 8:30 AM ET Company Participants Jon Lieber - U.S. Chief Financial Officer Roger Garceau - Interim CEO Phillip Schwartz - President of R&D Arthur Santora - Chief Medical Officer Conference Call Participants Operator Good morning, and welcome to Entera Bio's Conference Call to discuss the Financial and Operating Results from the Third Quarter of 2020. At this time, all participants lines are in a listen-only mode. After the speak ...

Entera Bio Ltd. (NASDAQ:ENTX) Q2 2020 Results Conference Call August 20, 2020 8:30 AM ET Company Participants Jon Lieber - U.S. CFO, Entera Roger Garceau - Interim CEO Dr. Phillip Schwartz - President of R&D Arthur Santora - Chief Medical Officer Conference Call Participants Brett Hoffman - Maxim Group Operator Good morning and welcome to Entera Bio's Conference Call to discuss the Interim Six Month Results from the EB613 Phase 2 Clinical Trial and the Financial and Operating Results from the Second Quarter ...

Call Start: 08:30 January 1, 0000 8:56 AM ET Entera Bio Ltd. (NASDAQ:ENTX) Q1 2020 Results Earnings Conference Call May 21, 2020, 08:30 AM ET Company Participants Jonathan Lieber - U.S. CFO, Entera Adam Gridley - CEO Phillip Schwartz - President of R&D Arthur Santora - Chief Medical Officer Conference Call Participants Operator Good morning and welcome to Entera BioÂ's Conference Call to discuss the Interim Biomarker Data from the Phase 2 clinical trial of EB613 and the Financial and Operative Results from ...

Entera Bio Ltd. (NASDAQ:ENTX) Q4 2019 Earnings Conference Call March 26, 2020 8:30 AM ET Company Participants Jonathan Lieber - U.S. CFO, Entera Adam Gridley - CEO Phillip Schwartz - President of R&D Arth Santora - Chief Medical Officer Conference Call Participants Naureen Quibria - Maxim Group Eric Rubenstein - Intuitive Venture Partners Operator Good morning and welcome to Entera Bio’s 2019 Financial and Operating Results Conference Call. At this time, all participants are in a listen-only mode. After the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | |--------------------------------------------------------------|---------------- ...